Literature DB >> 22064353

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.

T L Lasho, C M Finke, C A Hanson, T Jimma, R A Knudson, R P Ketterling, A Pardanani, A Tefferi.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22064353     DOI： 10.1038/leu.2011.320

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  40 in total

1.  Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Authors:  Mandy Brecqueville; Jérôme Rey; Raynier Devillier; Arnaud Guille; Rémi Gillet; José Adélaide; Véronique Gelsi-Boyer; Christine Arnoulet; Max Chaffanet; Marie-Joelle Mozziconacci; Norbert Vey; Daniel Birnbaum; Anne Murati
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

2.  U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.

Authors:  A Tefferi; C M Finke; T L Lasho; E A Wassie; R Knudson; R P Ketterling; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2013-10-07       Impact factor: 11.528

3.  Somatically acquired mutations in primary myelofibrosis: A case report and meta-analysis.

Authors:  Yongming Xia; Qingxiao Hong; Zhibin Gao; Shijun Wang; Shiwei Duan
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

4.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

5.  Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Bernadette Guerton; Lisa Pieri; Costanza Bogani; Denis Clay; Frederic Torossian; Jean-Jacques Lataillade; Hans C Hasselbach; Heinz Gisslinger; Jean-Loup Demory; Brigitte Dupriez; Claude Boucheix; Eric Rubinstein; Sophie Amsellem; Alessandro M Vannucchi; Marie-Caroline Le Bousse-Kerdilès
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

Review 6.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts.

Authors:  M M Patnaik; A Belachew; C Finke; T L Lasho; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528

Review 8.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

9.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

Review 10.  Splicing factor gene mutations in hematologic malignancies.

Authors:  Borja Saez; Matthew J Walter; Timothy A Graubert
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.